5 results for "survivin".
Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Alberto Carmona-Bayonas
Introduction: Grading of neuroendocrine lesions is often determined by Ki-67 (immunostain), despite limited prognostic ability for this cell cycle marker in well-differentiated tumors (WDNETs) and carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Dr Mark Kidd
Introduction: Lung carcinoids are well-differentiated neuroendocrine tumors (NETs) usually associated with a favorable prognosis. Mechanisms underlying progression are poorly understood.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MSc Dorian Swarts
Introduction: Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. Patricia Grabowski
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5 % of all thyroid malignancies. Although surgery remains the first line therapy with curative intention, for advanced MTC current chemotherapeutic regimes do not provide promising results. Consequently, the identification of biologically relevant biomarkers that are associated with MTC progression may provide novel therapeutic targets.
Conference: 13th Annual ENETS conference 2016 (2016)
Presenting Author: Dr. Andreas Krieg